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Abstract
Background: In Traditional Chinese Medicine (TCM) theory, functional dyspepsia (FD) can be divided into different
syndromes according to different clinical symptoms and signs, and the most common one is spleen-deficiency and
qi-stagnation syndrome that can be treated by Chinese traditional patent medicine —— two kinds of Zhizhu pills,
between which the primary difference in ingredients is that one contains immature orange fruit of Citrus
aurantium L.(IFCA) and the other contains that of Citrus sinensis Osbeck (IFCS). The trial’s objective was to compare
the efficacy of two kinds of Zhizhu pills on symptom changes in patients with FD of spleen-deficiency and qi-
stagnation syndrome.
Methods: A randomized, group sequential, double-blinded, multicenter trial was conducted in patients with FD of
spleen-deficiency and qi-stagnation syndrome at 3 hospitals in Beijing between June 2003 and May 2005.
Participants were randomly allocated into two groups (IFCA group and IFCS group) in a 1:1 ratio, and respectively
took one of the two kinds of Zhizhu pills orally, 6 g each time, 3 times a day, for 4 weeks. Statistical analysis was
performed with use of a group sequential method, the triangular test (TT).
Results: A total of 163 patients were randomized, and 3 patients were excluded from analysis because of early
dropouts, leaving 160 patients (IFCA group: n = 82; IFCS group: n = 78) for statistical analysis. Three interim
analyses were done after 62, 116, and 160 patients had completed their 4-week treatment, respectively. At the
third interim analysis, the sample path crossed the upper boundary and the trial was stopped, the cure-markedly
effective rates were 45% for IFCS group and 67% for IFCA group, respectively, the one-sided p-value was 0.0036,
the median unbiased estimate of the odds ratio (OR) for the benefit of IFCA relative to IFCS was 2.91 with 95%CI:
1.40 to 6.06.
No adverse events were observed in the two groups.
Conclusions: Zhizhu pills containing IFCA was superior to Zhizhu pills containing IFCS in the treatment of FD of
spleen-deficiency and qi-stagnation syndrome. The application of group sequential analysis in clinical trials of TCM
may offer some financial and ethical benefits.
Trial Registration: Chinese Clinical Trial Registry (ChiCTR): ChiCTR-TRC-00000485
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According to the proposition of an international commit-
tee meeting in Rome in 1991, the term “dyspepsia” refers
to pain or discomfort centered in the upper abdomen [1],
while discomfort refers to a subjective negative (or aver-
sive) feeling, such as early satiety, fullness, bloating and
nausea. In Rome I and Rome II reports [2,3], functional
dyspepsia (FD) is defined as a persistent or recurrent dys-
pepsia for at least 12 weeks in the preceding 12 months, if
there is no evidence for organic disease (including at
upper endoscopy) that could cause the symptoms. An epi-
demiological survey of western countries showed that the
prevalence of FD ranged from 11.5% to 14.7% [4]. It is also
a common clinical condition in China, and the report on
the incidence of FD in citizens of Tianjin, China, revealed
that the proportion of patients with FD reached 23.29% of
the total population [5].
In western medicine, the treatment of FD remains a
major unsolved problem in gastroenterology, and this is a
discouraging and unsatisfactory situation for treating
physicians.
In traditional Chinese medicine (TCM), FD is considered
nearly equivalent to the TCM term “stuffiness and fullness”
[6], which is divided into different syndromes according to
different clinical symptoms and signs. The basic syn-
dromes include liver-stomach disharmony syndrome (qi-
stagnation syndrome), fluid and food retention syndrome,
dampness-heat of spleen and stomach syndrome, spleen-
stomach weakness syndrome (spleen-deficiency syn-
drome), and cold and heat in complexity syndrome. It
should be noted that in clinical practice, qi-stagnation syn-
drome and spleen-deficiency syndrome often come
together, which is known as the spleen-deficiency and qi-
stagnation syndrome and can be treated by Chinese tradi-
tional patent medicine —— two kinds of Zhizhu pills [7].
Both of them are made from Rhizoma Atractylodis Macro-
cephalae (stir-baked) and Fructus Aurantii Immaturus
(immature orange fruit, stir-baked), while their primary
difference in ingredients is that one contains immature
orange fruit of Citrus aurantium L.(IFCA) and the other
contains that of Citrus sinensis Osbeck (IFCS). In clinical
practice, both Zhizhu pills have been considered to be
effective in the treatment of functional dyspepsia (FD) of
spleen-deficiency and qi-stagnation syndrome. The trial’s
objective was to compare the efficacy of two kinds of
Zhizhu pills on symptom changes in patients with FD of
spleen-deficiency and qi-stagnation syndrome.
Methods
Trial design
A randomized, group sequential, double-blinded, multi-
center trial was conducted in patients with FD of spleen-
deficiency and qi-stagnation syndrome at 3 hospitals in
Beijing between June 2003 and May 2005.
Participants
Based on the Rome-II criteria and the Guiding principle for
clinical research on new drugs of traditional Chinese medi-
cine (trial implementation) [6], patients with FD of spleen-
deficiency and qi-stagnation syndrome were enrolled in the
study. The spleen-deficiency and qi-stagnation syndrome is
defined as having the main symptoms and at least two of
the accompanying symptoms, as well as pale tongue with
whitish tongue coating and deep and thready pulse. The
main symptoms include epigastric stuffiness and fullness,
and asthenia. While the accompanying symptoms include
epigastric stuffiness and fullness aggravated after meal,
epigastric pain, decreased appetite, belching and acid regur-
gitation, fullness and discomfort in chest and hypochon-
drium, nausea and vomiting, and constipation or loose
stool. Other inclusion criteria included TCM syndrome
integral ≥8, aged 18 to 65 years old, and able and willing to
provide a signed and dated informed consent form.
Patients who had gastric ulcer or duodenal ulcer
revealed by upper gastrointestinal endoscopy, gastroeso-
phageal reflux disease with typical symptoms like heart-
burn or acid regurgitation, or any malignant diseases were
excluded from this study. Other exclusion criteria included
pregnant or breast feeding women as well as patients with
serious hepatic, cardiovascular, renal, or hematological dis-
eases. Patients with a known history of hypersensitivity to
Zhizhu pills were also excluded.
Interventions
Both kinds of Zhizhu pills (Approval No. granted by State
Food and Drug Administration of China (SFDA):
00406105), with a same instruction on usage and dosage,
were provided by the experimental pharmaceutical factory,
a subsidiary to China Academy of Chinese Medical
Sciences (CACMS). The pills should be taken 6 g orally
each time, 3 times a day after meals, for 4 weeks.
In addition to the above treatment, patients should not
receive any concomitant medications associated with the
treatment of this disease, and were also required to stop
taking such drugs at least 1 week before their study entry,
which include but not limited to anti-cholinergic drugs,
antispasmodic agents, emetic agents, H2 receptor antago-
nists, and any other gastric motility drugs. Moreover,
patients were also asked to stop smoking, drinking alcohol
or tea throughout the trial.
Outcomes
Primary outcome
We assessed each patient’s symptoms before and after
treatment by means of a rating scale (See Additional
file 1), which was completed by the treating physicians
when they interviewed their patients before and after
treatment (at baseline and week 4). The rating scale con-
sisted of 11 items (2 for the main symptoms, 7 for the
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2 (yes or no) or 4 options (absent, mild, moderate or
severe) for each item. Each option was represented by a
fixed score, the higher the score, the more severe the
symptom, and vice versa. The total score of the rating
scale was called syndrome integral.
Based on the efficacy standards for patients with FD
of spleen-deficiency and qi-stagnation syndrome
recommended in the “Guiding principle for clinical
research on new drugs of traditional Chinese medicine
(trial implementation)" [6], the overall efficacy was
judged as clinical recovery (the main symptoms and
signs disappeared or almost disappeared, and therapeu-
tic index ≥ 95%, which was defined as (1- after-treat-
ment syndrome integral/before-treatment syndrome
integral) ×100%, significant improvement (the main
symptoms and signs improved significantly, and 70% ≤
therapeutic index < 95%), somewhat improvement (the
main symptoms and signs somewhat improved, and
30% ≤ therapeutic index <70%), no change (therapeutic
index < 30%), somewhat worsening, and significant
worsening, etc.
For statistical convenience, the overall efficacy was cate-
gorized into 2 groups in this study. Clinical recovery and
significant improvement were judged as cured and mark-
edly improved, the cure-markedly effective rate, the pri-
mary outcome of this trial, was defined as the proportion
of patients achieving clinical recovery or significant
improvement; while somewhat improvement, no change,
somewhat worsening and significant worsening were
judged as not markedly improved.
Secondary outcome
The secondary outcome, gastric emptying rate, was
affected by the group sequential stopping rules. Therefore,
a conventional analysis of the secondary endpoints was
not planned in this study.
Randomisation and Allocation
A central-randomization scheme was performed in the
study. The random allocation sequence was generated and
conserved by the trial organizer, and participants were
randomly allocated into twog r o u p s( I F C Ag r o u pa n d
IFCS group) in a 1:1 ratio.
Blinding
This study was a double-blind clinical trial, with the
patients, the treating physicians, the statisticians, the
monitors and any other site personnel being unaware of
group allocation. Efforts to maintain blinding included
identical appearance, packaging and labeling of two kinds
of Zhizhu pills.
Unblinding should be done by the statisticians when
the data collection process was completed or the treat-
ing physicians when serious adverse events occurred.
Sample size
Before the trial was initiated, the sample size was calcu-
lated according to the following hypotheses: based on the
results of our previous study, we anticipated that the cure-
markedly effective rates were 40% for IFCS group and 55%
for IFCA group, respectively, and the type I and II error
rates were chosen at their usual values of 0.05 (one-sided).
Under these conditions, the required sample size with the
use of a single-stage design and a one-sided test would
have been 472 in total. Considering the recruitment-
related difficulties and ethical problems, we designed this
study with the triangular test (TT).
Statistical methods
The triangular test was designed to test H0: log odds ratio
θ = 0 with a (one-sided) type I error rate of a =0 . 0 5a n da
power of 1-b = 0.95 for θR = 0.6061. The interim analyses
were planned approximately after every 50 patients com-
pleted their 4-week treatment.
In brief, in the triangular test [8,9], two straight lines,
called the boundaries of the test, delineate a continuation
region (between these two lines), and the equations of the
boundaries are U: B = 6.5761+0.1515 V for the upper
boundary and L: B = -6.5761+0.4546 V for the lower
boundary.
The consecutive points (V, B), obtained from the data
collected at each analysis, define a sample path from the
left to the right of the continuation region. The trial
would be stopped to conclude that the IFCA group was
superior to the IFCS group if the sample path crossed
the upper boundary, stopped without that conclusion if
the sample path crossed the lower boundary, and con-
tinued otherwise. However, the definitive judgment of
whether to conclude that the IFCA group was superior
to the IFCS group could be based on whether the one-
sided p-value satisfied p ≤ 0.05.
Results
Study population
A total of 163 participants were included in the study, of
whom 3 (1 in the IFCA group and 2 in the IFCS group)
dropped out prematurely for personal reasons. The
remaining 160 participants were evaluable in the statisti-
cal analysis. All the results presented refer to this
population.
Participant flow
The flow of the participants in the study is summarized
in Figure 1.
Baseline data
Table 1 shows the general characteristics of evaluable
population. No significant differences were identified
between the two groups for any of these parameters,
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ment syndrome integral.
Primary outcome (sequential analysis)
Table 2 shows the cumulated numbers of evaluable
population at each step and the corresponding values of
the two statistics V and B computed for each sequential
analysis. Figure 2 represents the triangular test and the
corresponding sample path.
Three interim analyses were done after 62, 116, and
160 patients had completed their 4-week treatment,
respectively. At the third interim analysis, the sample
path crossed the upper boundary and the trial was
stopped. At stopping, the after-treatment syndrome
integral were 5.5 ± 2.1 for IFCA group and 6.3 ± 2.3
for IFCS group, the cure-markedly effective rates were
67% for IFCA group and 45% for IFCS group, the
one-sided p-value was 0.0036, the median unbiased
estimate of the odds ratio (OR) for the benefit of





Assessed for eligibility (n=202) 
Excluded  (n=39) 
   Not meeting inclusion criteria (n=31) 
   Declined to participate (n=6) 
   Other reasons (n= 2 ) 
Analysed  (n=82) 
 Excluded from analysis (give reasons) (n=0) 
Lost to follow-up (give reasons) (n= 0) 
Discontinued intervention (give reasons) (n= 1) 
Allocated to the IFCA group (n=83) 
 Received Zhizhu pills (containing IFCA) 
(n=83) 
 Did not receive Zhizhu pills (containing IFCA) 
(give reasons) (n= 0) 
Lost to follow-up (give reasons) (n= 0) 
Discontinued intervention (give reasons) (n=2) 
Allocated to the IFCS group (n=80) 
 Received Zhizhu pills (containing IFCS)  (n= 
80) 
 Did not receive Zhizhu pills (containing IFCS)  
(give reasons) (n= 0) 
Analysed  (n=78) 






Figure 1 The flow of the participants in the study.
Table 1 Baseline patient characteristics
Characteristic IFCS(n = 78) IFCA(n = 82)
Gender(male/female) 22/56 31/51
Age(years) 47.2 ± 13.3 48.6 ± 14.5
Course of disease(months) 19.6 ± 20.5 17.4 ± 21.6
Before-treatment
syndrome integral
17.3 ± 4.8 17.0 ± 4.3
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Throughout the trial, the two kinds of Zhizhu pills were
generally safe and well-tolerated by all patients. No
major adverse events were observed in the two groups.
Discussion
During the past two decades, the pathophysiology of FD
has been under investigation, and multiple mechanisms
such as abnormal gastric emptying, visceral hypersensitiv-
ity, impaired gastric accommodation and central nervous
system factors are likely involved. So the possibilities of
pharmacological therapy for FD are still limited, however,
experience of using prokinetics, tricyclic antidepressants,
selective serotonin-reuptake inhibitors (SSRIs), proton-
pump inhibitors (PPIs), and several alternative techniques
(such as acupuncture, multicomponent herbal medications
and hypnotherapy) has been accumulated [10]. Although
the efficacy of some established treatments (e.g. antisecre-
tory agents or prokinetics) has been proven in placebo-
controlled trials, the majority of these trials have shown
only minor advantages of these drugs compared with pla-
cebo [11,12], spontaneous improvement may partially
explain at least part of the placebo response [13].
In many countries, some physicians use various herbal
medications for the treatment of FD, and their clinical
experience appears to support the use of the treatments,
but the efficacy of these treatments has been lacking the
supporting of randomized controlled studies in the past
decades. Recently, several well-designed placebo-con-
trolled clinical trials have provided evidence for the effi-
cacy of herbal medications used in the treatment of
dyspepsia [14].
Based on the concept of TCM, two kinds of Zhizhu pills
can be used to treat FD of spleen-deficiency and qi-stagna-
tion syndrome. But the efficacy of most herbal medica-
tions is influenced by many factors which may lead to
unstable efficacy in clinical practice. These factors include
the differences in the variety of Chinese medicinal herbs,
growing areas, harvesting seasons and the processing and
preparing of these herbs, etc., of which the variety is a
most influential factor. Thus, it is of great importance to
make a comparison of a same prescription made from dif-
ferent varieties of a medicinal herb so as to further
improve its clinical efficacy.
Pharmacological experiments [15] have indicated that
the bioavailability of Zhizhu pills containing IFCA was
superior to those containing IFCS, because flavonoid com-
pounds such as naringin and hesperidin, which can be
converted to naringenin and hesperitin in the body and
affect the gastrointestinal motility, are part of the sub-
stance basis for the efficacy of Zhizhu pills in treating
abdominal distension, and the pharmacokinetic para-
meters after the administration of two kinds of Zhizhu
pills have shown that the sum AUC of naringenin and
hesperitin of Zhizhu pills containing IFCA was much big-
ger than that of Zhizhu pills containing IFCS, which indi-
cated that the efficacy of the former was superior to the
latter, this conclusion was consistent with the findings of
our study.
As for the methodological aspects of our study, if the
classic single-stage design (SSD) was applied, the sample
size needed would have been 472 patients. But given the
difficulties encountered in recruitment of eligible patients,
it was most likely that it would not have been possible, in
only three centers, to bring this study to its end within
three years. Moreover, since the primary outcome could
be obtained relatively quickly when compared with the
recruitment rate, this trial was planned with a group
sequential design.
In group sequential designs, the sample size is a ran-
dom variable whose distribution depends on the true
treatment difference and on the stopping rule used. For
this trial, triangular test (TT) was considered to be
appropriate, the TT is a special case of a class of
sequential designs developed by Andersonthis [16]and
advocated by Whitehead [8,17]. Veronique et al. [18]
indicated that the TT, of the sequential tests, seems to
be the most appealing with regard to statistical proper-
ties: type I and II errors are correctly maintained to
their desired values, and it offers a substantial decrease
in sample size compared not only with single-stage
Table 2 Cumulative results for the triangular test applied
to the trial in FD of spleen-deficiency and qi-stagnation
syndrome
Analysis nIFCA nIFCS SIFCA FIFCA SIFCS FISCS BV
1 32 30 20 12 14 16 2.45 3.83
2 60 56 38 22 26 30 4.89 7.16
3 82 78 55 27 35 43 8.89 9.82
Figure 2 Design of the triangular test (upper boundary, B =
6.5761+0.1515 V; lower boundary, B = -6.5761+0.4546 V) and
the results of the three sequential analyses for the comparison
of two kinds of Zhizhu pills. On the third analysis, the sample
path crossing the upper boundary indicates the Zhizhu pill
containing IFCA is superior.
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whatever the frequency of the analyses. Simulation stu-
dies indicated that [19] the use of a TT-based sequential
analysis design brought about a 50% reduction of the
average sample needed, when compared to the fixed-
sample design. In this study, using the TT-based
sequential analysis, we saved 66% of the patient sample
size. Moreover, patient recruitment in the study could
be stopped shortly after 20 months from the recruit-
ment of the first patient, which saved much time since
the recruitment were initially planned about a five year
period. This study also complied with ethical require-
ments and could make a case for wider use of group
sequential designs in TCM clinical trials.
The statistical hypotheses made in the planning phase
were drawn from our previous experience. At the third
analysis, the upper boundary was crossed, allowing the
trial to be stopped, and the computations [9] provided
the one-sided p-value which was just the one-sided type
I error of this design, the resulting value was p =
0.0036, so we can conclude that Zhizhu pills containing
IFCA was superior to Zhizhu pills containing IFCS.
There are some discrepancies in the literature [20]
about the cure-markedly effective rate of Zhizhu pills in
treatment of FD. In our opinion, differences in the diag-
nosis of the syndrome and the definition of the cure-
markedly effective rate may be possible explanations.
The major advantage of group sequential designs lies
in the early stopping. However, the decision to stop a
study early involves ethical, administrative, economic
and not just statistical consideration. Statistics should be
considered as a tool, which could trigger the procedure
to stop a trial but statistics cannot supplant a trial safety
committee.
Our study inevitably had its limitations. The trial,
ended in May 2005, adopted the Rome II criteria, which
was modified in 2006 (the Rome III criteria). The Rome
I and II criteria did not account for meal-related symp-
toms and this was the fundamental change in Rome III
criteria [21]. The other limitation of the present study
was the lack of a treatment arm using placebo. In order
to further investigate the efficacy of Zhizhu pills con-
taining IFCA in the treatment of FD, a randomized pla-
cebo-controlled clinical trial is required.
Conclusions
Zhizhu pills containing IFCA was superior to Zhizhu
pills containing IFCS in the treatment of FD of spleen-
deficiency and qi-stagnation syndrome. And the triangu-
lar test was successfully applied to this study, and
offered some financial and ethical benefits. Thus, for
future TCM clinical trials, a group sequential design
should remain a strong consideration.
Additional material
Additional file 1: The Rating Scale for FD of Spleen-deficiency and
Qi-stagnation Syndrome. The rating scale consisted of 11 items with 2
or 4 options for each item. Each option was represented by a fixed
score. The Before-treatment score and After-treatment score were
assessed at the 0th and (28 ± 2)th day of the trial respectively. Total
score was called syndrome integral.
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